News coverage about Summit Therapeutics (NASDAQ:SMMT) has been trending somewhat positive on Thursday, according to Accern. The research firm identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Summit Therapeutics earned a daily sentiment score of 0.06 on Accern’s scale. Accern also assigned headlines about the company an impact score of 45.404885371462 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Shares of Summit Therapeutics stock opened at $13.47 on Thursday. The firm has a market cap of $181.36, a price-to-earnings ratio of -134.70 and a beta of 0.93. Summit Therapeutics has a 52 week low of $8.80 and a 52 week high of $16.86.
A number of research analysts have issued reports on the stock. Zacks Investment Research lowered shares of Summit Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, March 8th. ValuEngine upgraded shares of Summit Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, March 2nd. HC Wainwright set a $16.00 price target on shares of Summit Therapeutics and gave the company a “buy” rating in a research note on Wednesday, December 27th. SunTrust Banks assumed coverage on shares of Summit Therapeutics in a research note on Thursday, January 4th. They set a “buy” rating and a $24.00 price target on the stock. Finally, BTIG Research assumed coverage on shares of Summit Therapeutics in a research note on Tuesday, February 13th. They set a “buy” rating and a $33.00 price target on the stock. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Summit Therapeutics has a consensus rating of “Buy” and a consensus price target of $24.17.
COPYRIGHT VIOLATION NOTICE: “Summit Therapeutics (SMMT) Given Daily Media Impact Score of 0.06” was originally reported by BBNS and is the property of of BBNS. If you are accessing this piece on another website, it was illegally copied and republished in violation of international copyright & trademark laws. The original version of this piece can be accessed at https://baseballnewssource.com/2018/03/22/summit-therapeutics-smmt-receiving-somewhat-favorable-press-coverage-study-finds/1925693.html.
Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).
Receive News & Ratings for Summit Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.